COTY · COTY INC

Current Thesis

Coty's balance-sheet-repair thesis has lost its price confirmation: the September 18 close breached the published invalidation level, while a completed Consumer Beauty transaction and lower reported leverage remain the tests of fundamental repair. The adjusted close of $2.43 on 2026-09-18 was below the $2.55 threshold published on 2026-09-05. That condition has occurred; the earlier thesis cannot remain active merely because the strategic review remains unfinished.

For the previously published recovery leg, the narrative is dead — the 2026-09-18 close establishes that its price condition failed. This is an inference about the market structure, not a finding that the company cannot complete its restructuring. The supplied observations do not establish the first breach date.

At 2026-06-30, financial net debt was $2,912.1 million and reported leverage was 3.4 times adjusted earnings before interest, taxes, depreciation and amortization (EBITDA). Those are the disclosed benchmarks against which further balance-sheet repair can be assessed. Coty's 2026-08-19 results.

Bullish and bearish views on COTY INC

The model's bull view on COTY INC (COTY), in brief: Cash generation provides tangible support. The bear view: Earnings contraction limits debt repair. Both cases follow in full.

Bull Case

• Cash generation provides tangible support. Fiscal 2026 free cash flow was $348.2 million; management's 2026-08-19 outlook projected more than $300 million for the first half of fiscal 2027. The latter remains guidance. Results release.
• Gucci proceeds have a schedule. The 2026-08-19 disclosure records $250 million received at signing and another $150 million due no later than 2027-09-30, including up to $30 million contingent on specified criteria. The full consideration is not immediate cash. Agreement disclosure.

Bear Case

• Earnings contraction limits debt repair. Fiscal 2026 adjusted EBITDA fell 22% to $846.9 million, as reported on 2026-08-19. Lower debt alone does not establish a lower leverage ratio. Results release.
• The market condition already failed. The 2026-09-18 adjusted close of $2.43 breached the September 5 research threshold of $2.55. A lower replacement threshold would change the original test after failure.

Setup & Price Structure

The measured change since the previous note is deterioration in price: the market closed at $2.93 on 2026-09-04 and $2.43 on 2026-09-18. The latest supplied series still shows a three-month gain of 27.2%, alongside a 14-day relative strength index (RSI) of 23.1. A positive trailing return and weak recent momentum can coexist; neither establishes a new base.

The September 18 snapshot places the shares 45.4% below the trailing 52-week high of $4.45. No moving-average value or trading-volume series is available here, so distance above a rising average and changes in participation cannot be established. The $2.55 level remains the failed research threshold, rather than demonstrated current support.

The September 4 positioning snapshot cited in the September 5 note recorded short interest of 43.25 million shares, equivalent to 4.91% of shares outstanding. That denominator is outstanding shares, not freely tradable shares, and the snapshot is not a September 18 measurement. It does not establish current crowding or a squeeze mechanism.

Catalyst Calendar (next 30 days)

For 2026-09-19 through 2026-10-19, no company-confirmed catalyst was identified in the reviewed calendar material. The company event record identifies the completed 2026-08-20 earnings call; it is not an upcoming event.

• 2026-12-31 — Strategic-review deadline. Management's 2026-08-19 statement expects Consumer Beauty review completion by calendar year-end; this is a deadline interpretation, not a scheduled announcement. Full-year guidance remains deferred. Company outlook.

What Would Change Our Mind

The loss of the published recovery threshold has already settled the original price test: a daily close below $2.55 invalidates that leg, and the 2026-09-18 close of $2.43 satisfies it. A subsequent recovery would not erase this dated outcome.

A different fundamental assessment would require disclosed transaction terms and reported leverage below the 3.4-times fiscal-year-end benchmark. Reaching 2026-12-31 without a defined Consumer Beauty outcome would fail the remaining deadline-dependent case. A completed review alone would not establish debt reduction without proceeds, liabilities transferred and the earnings retained being disclosed.

Correlation Notes

This remains a single-company restructuring case. The 2026-09-18 price snapshot contains no paired peer or index return series, so it cannot establish that Coty's three-month gain of 27.2% reflects a broader consumer-discretionary rotation. The available sample is insufficient to support a correlation claim; the measurable tests remain Coty's own transaction disclosures, leverage and published price condition.